Residency · Residency · Medical Genetics Genomics

Li-Fraumeni Syndrome and TP53 Germline Variants

TP53 Gene and Protein

Function

The TP53 gene, located at 17p13.1, encodes the p53 protein, widely known as the "guardian of the genome." This master tumor suppressor integrates cellular stress signals and directs cell fate decisions including cell cycle arrest, DNA repair, senescence, and apoptosis. The protein is activated by diverse stresses including DNA damage, oncogene activation, hypoxia, nucleotide depletion, and ribosomal stress. Its downstream effectors include p21 (mediating cell cycle arrest), BAX and PUMA (driving apoptosis), MDM2 (providing negative feedback regulation), and GADD45 (facilitating DNA repair). Functionally, p53 operates as a homotetramer, which means that dominant-negative missense mutations in a single allele can impair the function of the entire tetrameric complex.

Variant Types

Approximately 70% of pathogenic TP53 variants are missense changes, predominantly concentrated in the DNA-binding domain encoded by exons 5-8. Hotspot codons include R175H, G245S, R248W/Q, R249S, R273H/C, and R282W. Dominant-negative variants produce mutant p53 that incorporates into tetramers and disrupts wild-type p53 function, and these are associated with earlier cancer onset. Some missense mutations also confer gain-of-function properties beyond simple loss of function, actively promoting invasion and chemoresistance. Loss-of-function variants (nonsense and frameshift mutations) operate through haploinsufficiency and may produce relatively later onset compared to dominant-negative variants.

Clinical Spectrum

Core LFS Cancers

Breast cancer is the most common malignancy in female Li-Fraumeni syndrome (LFS) patients, typically presenting premenopausally and often HER2-positive, with an approximate 54% lifetime risk. Soft tissue sarcomas occur throughout life, with rhabdomyosarcoma predominating in children. Osteosarcoma typically arises in adolescence or young adulthood. Brain tumors include choroid plexus carcinoma (highly specific for LFS in infancy), medulloblastoma, glioma, and astrocytoma. Adrenocortical carcinoma (ACC) in childhood shows greater than 50% association with germline TP53 variants, with the R337H Brazilian founder variant particularly strongly associated.

Additional Associated Cancers

The LFS cancer spectrum extends to leukemias and lymphomas in childhood, lung adenocarcinoma in non-smokers, colorectal cancer, gastric cancer, ovarian cancer, melanoma, and renal cell carcinoma. Virtually any cancer type can occur in the context of LFS, necessitating vigilance across all organ systems.

Cancer Risk Estimates

Approximately 50% of carriers develop cancer by age 30, rising to roughly 90% by age 60. Females have higher lifetime cancer risk (approaching 100%) than males (approximately 73%), largely driven by breast cancer. Multiple primary cancers develop in up to 50% of patients. Radiation exposure can induce secondary malignancies, and therapeutic radiation should be minimized whenever equivalent alternatives exist.

Diagnostic Criteria

Classic Li-Fraumeni Syndrome Criteria (1988)

The original criteria require a proband with sarcoma diagnosed before age 45, a first-degree relative with any cancer before age 45, and another first- or second-degree relative with any cancer before age 45 or sarcoma at any age.

Chompret Criteria (Revised)

The Chompret criteria are the most widely used for guiding TP53 testing. They are met by any of the following: a proband with a core LFS tumor before age 46 plus at least one first- or second-degree relative with a core tumor before age 56 or multiple primaries; a proband with multiple primary tumors (two of which are core LFS tumors) first diagnosed before age 46; a proband with adrenocortical carcinoma, choroid plexus carcinoma, or rhabdomyosarcoma (embryonal or anaplastic) at any age regardless of family history; or breast cancer before age 31.

Practical Testing Approach

Multigene panel testing increasingly identifies TP53 variants incidentally in cancer patients who do not meet classic criteria. All children with adrenocortical carcinoma or choroid plexus carcinoma should be tested for TP53 mutations. Testing should also be considered in any patient with multiple primary cancers or cancer diagnosed before age 30.

Surveillance: The Toronto Protocol

Whole-Body MRI (WBMRI)

Annual whole-body MRI forms the cornerstone of LFS surveillance, recommended from birth or from the time of molecular diagnosis. It detects early-stage cancers across multiple organ systems without radiation exposure. Evidence from the Toronto protocol demonstrated that WBMRI-based surveillance improved 5-year overall survival to greater than 90%, compared to approximately 60% in unsurveilled carriers. The protocol includes rapid MRI sequences covering brain, chest, abdomen, pelvis, and extremities.

Component-Specific Surveillance

Brain MRI with contrast is performed annually, alternating with WBMRI. Breast surveillance begins with annual breast MRI at age 20; mammography is not recommended before age 30 due to radiation avoidance principles, and risk-reducing mastectomy should be discussed. Abdominal ultrasound is performed every 3-4 months in children for adrenocortical carcinoma screening. Blood work includes CBC for leukemia screening, urinalysis, and cortisol/DHEA-S in children. Colonoscopy begins at age 25 (or 10 years before the youngest colorectal cancer in the family) and is repeated every 2-5 years. Annual dermatologic examination screens for melanoma.

Radiation Avoidance

Diagnostic ionizing radiation should be minimized, with MRI and ultrasound preferred over CT. Therapeutic radiation should be reserved for situations where no equivalent alternative exists, and radiation risks must be explicitly discussed in treatment planning. TP53 variants confer both radiosensitivity and elevated risk of radiation-induced secondary cancers. Chest CT for lung cancer screening remains controversial in LFS due to radiation concerns, with some protocols substituting chest MRI.

Controversies

Incidental TP53 Findings on Multigene Panels

TP53 variants are found in approximately 0.2-0.5% of multigene panel tests, often in patients who do not meet LFS criteria. Many of these may represent clonal hematopoiesis of indeterminate potential (CHIP) rather than true germline variants, or they may be low-penetrance variants or mosaic somatic variants in blood. CHIP involves age-related somatic TP53 mutations in hematopoietic cells that are detected on testing intended to identify germline variants. Confirmation on a non-hematopoietic tissue source (skin fibroblasts or buccal cells) is essential before diagnosing LFS.

Testing Minors

The occurrence of childhood cancers in LFS (ACC, choroid plexus carcinoma, rhabdomyosarcoma) justifies testing and surveillance from birth, providing a strong argument for testing children since surveillance and early detection are effective. However, testing also reveals adult-onset cancer risk and may impose psychological burden. Professional guidelines support TP53 testing in minors when surveillance will be initiated as a result.

Reproductive Decision-Making

Preimplantation genetic testing for monogenic disorders (PGT-M) is available and frequently used by TP53 carriers. Nondisclosure PGT is rarely but occasionally requested. Prenatal testing is available but requires complex ethical discussions. The decision to test a child versus waiting until adulthood remains a source of ongoing debate.

Genotype-Phenotype Considerations

Dominant-negative variants such as R175H, R248W, and R273H are associated with earlier cancer onset than null variants. The R337H Brazilian founder variant demonstrates lower penetrance and is primarily associated with childhood ACC, with a carrier frequency of approximately 0.3% in southern Brazil. Functional assays including yeast-based and mammalian cell-based systems help characterize variant impact, and the IARC TP53 database provides comprehensive variant data. The distinction between loss-of-function and gain-of-function variants influences prognosis and emerging therapeutic strategies.

<image>A timeline diagram showing the cancer spectrum and surveillance protocol for Li-Fraumeni syndrome across the lifespan. The x-axis represents age (0-70 years). Above the timeline, common cancer types are shown at their typical age of onset: choroid plexus carcinoma and ACC in infancy/early childhood, rhabdomyosarcoma and osteosarcoma in adolescence, breast cancer in young adulthood, and soft tissue sarcomas and other cancers throughout life. Below the timeline, surveillance components are displayed as horizontal bars: whole-body MRI (from birth, annually), brain MRI (annually), breast MRI (from age 20), abdominal ultrasound (every 3-4 months in children), colonoscopy (from age 25), and blood work (annually). Color coding distinguishes pediatric from adult surveillance protocols.</image>

<image>A molecular diagram of p53 function and the dominant-negative effect. Panel 1: Normal p53 activation -- DNA damage triggers p53 stabilization, tetramerization of four wild-type p53 monomers, binding to p53 response elements, and transcriptional activation of target genes (p21 for cell cycle arrest, BAX for apoptosis, MDM2 for feedback regulation). Panel 2: Dominant-negative effect -- one mutant p53 monomer (highlighted in red) incorporated into the tetramer distorts the DNA-binding domain, preventing the entire tetramer from binding DNA, resulting in loss of tumor suppressor function. Panel 3: Gain-of-function -- mutant p53 acquires ability to interact with novel protein partners and activate oncogenic transcription programs, promoting invasion and chemoresistance.</image>

<image>A decision flowchart for managing an incidental TP53 variant found on a multigene panel. Starting with "TP53 variant identified on germline panel testing from blood," the flowchart branches: First, assess if the variant could represent CHIP (clonal hematopoiesis) by checking patient age, variant allele frequency (if significantly different from 50%), and whether the variant is a known CHIP hotspot. If CHIP is suspected, test a non-hematopoietic tissue (skin fibroblast or buccal swab). If confirmed germline: assess variant pathogenicity, review personal and family cancer history, initiate LFS surveillance. If CHIP (present in blood only, absent in other tissue): not LFS, but monitor for hematologic malignancy. The critical distinction between germline TP53 (LFS) and somatic CHIP is emphasized.</image>

Clinical Pearls

Choroid plexus carcinoma in a child and adrenocortical carcinoma at any age should prompt immediate TP53 germline testing regardless of family history, as these cancers have greater than 50% association with germline TP53 variants. Whole-body MRI-based surveillance has been shown to improve survival in TP53 carriers and is the cornerstone of LFS management, offered from birth or time of molecular diagnosis. Therapeutic ionizing radiation should be minimized in TP53 carriers due to increased risk of radiation-induced secondary cancers; MRI and ultrasound are preferred for diagnostic imaging. Clonal hematopoiesis (CHIP) is an increasingly recognized confounder when TP53 variants are identified on blood-based multigene panels, and confirmation on a non-hematopoietic tissue is essential before diagnosing LFS, especially in older patients. Breast cancer in LFS is often HER2-positive and premenopausal, and risk-reducing mastectomy should be discussed since breast MRI screening alone may not be sufficient given the very high lifetime risk. The dominant-negative mechanism of missense TP53 variants means that heterozygous carriers often have more severe loss of p53 function than expected from simple haploinsufficiency, contributing to the very high cancer penetrance. Multiple primary cancers are common in LFS (up to 50% of patients), and each new cancer diagnosis in a known TP53 carrier should be evaluated independently with treatment plans that minimize mutagenic exposures.

References

• Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-752.
• Villani A et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome. Lancet Oncol. 2011;12(6):559-567.
• Bougeard G et al. Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. J Clin Oncol. 2015;33(21):2345-2352.
• Kratz CP et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(11):e38-e45.
• Fortuno C et al. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants. Hum Mutat. 2021;42(3):223-236.
• Coombs CC et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell. 2017;21(3):374-382.

Read this lecture as Markdown